主页 > 生命科学 >
【原创】中外公司上半年销售额低于预期目标
据日本中外（Chugai）公司上半年临时财务报告显示，截至6月30日，该公司销售总额达1419亿日元（13亿美元），比预期目标少了21亿日元。
中外公司将这次亏缺归咎于一些新产品在日本市场占有速度上的不尽人意，最明显的是于去年12月作为首个聚乙二醇化干扰素上市的丙肝治疗药派罗欣(Peginterferon alfa-2a，Pegasys)，该品上半年预期销售额为39亿日元，实际只完成了23亿日元。
由于支柱产品完成较好，如抗贫血药依泊丁(epoetin beta，Epogin) 和治白细胞减少的来诺拉提(lenograstim，Neutrogin)都达到了内定目标，销售额分别为320亿日元和130亿日元；加上公司将部分促销和研发费用转移到了下半年账上以及其它费用的节省，上半年利润指标终于完成：整体营运利润比预期目标221亿日元高出36亿日元，净利润比预期目标138亿日元高出23亿日元。
其他产品也为公司上半年业绩的获得作出了贡献，如流感用药奥司他韦( Oseltamivir ，Tamiflu)销售额达72亿日元，绝经后骨质疏松症治疗药雌激素拮抗剂雷洛昔芬 (raloxifene, Evista，与礼莱共同销售)自五月份投入市场后，赢得销售额15亿日元。
奥司他韦的75mg胶囊剂用于预防A/B型流感的附加适应症也已在日本得到正式批准。公司强调说该品并非旨在替代疫苗，其新用途更加适合于出现症状的流感患者的家人。
该药获准用于治疗13岁以上的病人包括高危人群，如65岁以上或有呼吸系统病症的患者，有慢性心脏病/新陈代谢疾病或肾机能障碍者。标准的给药方案是在与流感病人接触的两天之内，每日服药一次，持续服用7到10天。
S00850746 - Scrip Top
Date published: 14 July 2004
Chugai first-half sales below target
Chugai's provisional results for the first half ended June 30th showed consolidated total sales of ¥141.9 billion ($1.3 billion), ¥2.1 billion below the company's forecast. Comparative figures are not available because of a change in fiscal year-end to December in line with its parent, Roche.
Chugai attributed the shortfall to slower than expected penetration of some newer products in Japan, notably Pegasys (peginterferon alfa-2a) for hepatitis C, which was launched last December as the first pegylated interferon in this market. Sales of ¥3.9 billion were forecast for the six months but came in at only ¥2.3 billion. Overall operating profit was ¥3.6 billion ahead of target, however, at ¥22.1 billion and net profit was ¥2.3 billion above expectations at ¥13.8 billion. Both were helped by a shift of some promotional and R&D expenses to the second half and other cost savings.
Among mainstay products, both Epogin (epoetin beta) and Neutrogin (lenograstim) were roughly in line with internal targets, at ¥32 billion and ¥13 billion respectively. Sales of the flu treatment, Tamiflu (oseltamivir), were ¥7.2 billion while Chugai's sales of Evista (raloxifene, co-marketed with Lilly) were ¥1.5 billion since its launch for postmenopausal osteoporosis in May.
Roche will announce its first-half results, including Chugai, on July 21st and Chugai will release its own final figures on August 3rd.
. . . Tamiflu prophylactic use
The 75mg capsule formulation of Tamiflu has now been formally approved in Japan for the additional but non-reimbursed indication of prophylaxis of type A/B influenza. Chugai stresses that the product is not designed to replace vaccination and that the new use is aimed more specifically at family members of patients displaying symptoms.
The approval is for those over 13 years old and includes use in higher-risk individuals such as those over 65 or with respiratory disorders, chronic cardiac/metabolic disease or renal dysfunction. The standard dosing regimen is once daily within two days of contact with flu patients for seven to 10 days.
Full title: SCRIP - World Pharmaceutical News
FILED 14 July 2004 COPYRIGHT 2004 PJB Publications Ltd [标签:content1][标签:content2]
阅读本文的人还阅读：
作者:admin@医学,生命科学 2011-02-24 05:14
医学,生命科学网